Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modafinil Augmentation of Escitalopram for Post-Stroke Depression
IRCT20231106059971N1Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of modafinil and escitalopram in major depressive disorder (MDD), sponsored by University of Social Welfare and Rehabilitation Sciences. Primary endpoints: Depressive symptoms improvement, Cognitive symptoms improvement and 1 more. Started Jan 2024; status: completed.
02
Drugs
modafinilescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20231106059971N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231106059971N1.